QUICK READ
Ignota Labs has raised £5.5m in a seed funding round co-led by Montage Ventures and AIX Ventures, with participation from Modi Ventures, Blue Wire Capital, and Gaingels. Founded by Sam Windsor, Jordan Lane, and Layla Hosseini-Gerami, the company applies AI-driven drug discovery to rescue promising therapies that have failed due to safety concerns.
Its SAFEPATH platform uses deep learning, cheminformatics, and bioinformatics to identify and resolve drug toxicity issues, enabling abandoned drug candidates to be revived and progressed toward clinical trials. The company has already in-licensed its first asset, a metabolic health drug targeting post-menopausal women, successfully resolving previous safety concerns through preclinical validation.
The new capital will support the expansion of its pipeline by acquiring additional distressed drug assets and advancing its first therapy, a PDE9A inhibitor, into early-stage clinical trials.
